Vera Therapeutics (VERA)

Executive Summary

Vera Therapeutics is a clinical-stage biotechnology company focused on developing atacicept, a first-in-class TACI-Fc fusion protein that targets B-cell and plasma cell pathways underlying autoimmune diseases. The company's lead candidate, atacicept, is in Phase 3 development for IgA nephropathy (IgAN), a serious kidney disease with high unmet need. Positive Phase 2b data demonstrated significant reduction in proteinuria and stabilization of eGFR, supporting accelerated progression. Atacicept also shows promise in primary membranous nephropathy (pMN) Phase 2 trials. With a strong cash position and a clear regulatory pathway, Vera is positioned to become a leader in B-cell mediated renal diseases. The upcoming Phase 3 ORIGIN trial top-line results represent a pivotal value inflection point, with potential to support a Biologics License Application submission.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 ORIGIN Trial Top-Line Results70% success
• H1 2027Phase 2 pMN Interim Data Readout50% success
• TBDPotential Partnership or Licensing Deal for Atacicept60% success